The analyst cut Ameriprise from Buy to Underperform and lowered the target from $570 to $445. That signals a weaker view, with no company results or positive news in the article pointing the other way.
The lower rating signals less confidence in Ameriprise's business prospects. The article reports no company results or favorable news pointing the other way, so the analyst's change drives the reading.
BXP's analyst moved it from Overweight to Neutral and cut the target from $72 to $64. This points to a weaker view of BXP.
MDxHealth's analyst moved its rating from Buy to Neutral. That signals less confidence in the company, and the article gives no positive company news to balance it.
A.O. Smith's analyst moved it from Buy to Hold and cut the target from $70 to $59. This points to a weaker view of the company.
Follow Ameriprise Financial, Inc. (AMP) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for AMP